

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning on page 19, ¶ [0098] with the following rewritten paragraph:

According to the present invention, before identification, a distribution map for DNA sequences including microsatellite genetic polymorphism markers, which are used to indicate the nucleotide sequence and location in each DNA sequence of a group of DNA sequences including microsatellite genetic polymorphism markers that are located in advance on the human genome at desired intervals, is made and utilized. In actuality, the inventors prepared a group of DNA sequences including microsatellite genetic polymorphism markers on the human genome, and made and utilized a distribution map including the group of DNA sequences made up of all or a part of the nucleotide sequence referenced with sequence numbers 1 to 27088. Usage of this distribution map has enabled gene mapping throughout a genome according to the present invention. It is noted that Golden Path (Dec. 22, 2001) (~~<http://genome.ucsc.edu/>~~) is used as the human genome reference sequence, which is utilized for making the distribution map.

Please replace the paragraph beginning on page 47, ¶ [0218] with the following rewritten paragraph:

Using the method described in Embodiment 1, genome correlation analysis of the susceptibility gene for psoriasis vulgaris is carried out. This screening allows identification of the gene locus extending from the centromeric MICB gene of the sixth chromosome to the telomeric HLA-F gene, and identification of 758 microsatellite loci **having 2- to 5-nucleotide repeats** existing ~~from 2'- to 5'-~~ **nucleotide** within the 1.8 Mb HLA class I region including the HLA-B and the HLA-C gene. This fact corresponds to conventional reports (Mizuki N. et al. (1997) Genomics, 42, 55-66; Shiina T. et al. (1998) Genomics, 47, 372-382; Shiina T. et al. (1999) Immunol Rev., 167, 193-199; Tamiya G. et al. (1998) Tissue Antigens, 51, 337-346).

AMENDMENTS TO THE SPECIFICATION, CONT.

Please replace the paragraph beginning on page 57, ¶ [0244] with the following rewritten paragraph:

In the second screening, analysis of 102 markers that have been identified as **positive negative** by the first screening is carried out. Using other DNA samples, which are different from the DNA samples used for the first screening, the pooled DNA samples to be used for the second screening are prepared and a test is carried out.